Article Text

Download PDFPDF

4CPS-287 Impact of SARS-CoV-2 infection in acute myeloid leukaemia patients: experience of the Pethema registry
  1. T Palanques Pastor1,
  2. J Megias Vericat1,
  3. P Martinez2,
  4. J Cornago Navascués3,
  5. JL López Lorenzo3,
  6. G Rodríguez4,
  7. I Cano5,
  8. M Arnan Sangerman6,
  9. JL Poveda Andrés1,
  10. P Montestinos1
  1. 1Hospital Universitari i Politècnic La Fe, Pharmacy Service, Valencia, Spain
  2. 2Hospital Universitario 12 de Octubre, Haematology and Haemotherapy Service, Madrid, Spain
  3. 3Hospital Universitario Fundación Jiménez Díaz, Haematology and Haemotherapy Service, Madrid, Spain
  4. 4Hospital General Universitario Gregorio Marañón, Haematology and Haemotherapy Service, Madrid, Spain
  5. 5Hospital Universitari I Politècnic La Fe, Haematology and Haemotherapy Service, Valencia, Spain
  6. 6Instituto Catalán de Oncología, Clinic Haematology Service, Hospitalet de Llobregat, Spain


Background and importance SARS-CoV-2 infection can impact the survival of patients with acute myeloid leukaemia (AML) but there is little published evidence in AML.

Aim and objectives To analyse the clinical futures and outcome of SARS-CoV-2 infection in AML patients.

Material and methods An observational multicentre study was conducted between March and May 2020 with 117 patients reported from 47 Spanish centres. Leukaemic and viral infections were studied, and inter-relationships were established.

Results Median age was 68 years, men (56.7% vs 43.3%), median time from AML diagnosis to SARS-CoV-2 was 4 months and mean number of comorbidities was 1.2. Cytogenetic risk was low in 16.9%, intermediate in 57.1% and high in 26.0%; 55.7% had active disease, 39.2% complete remission and 5.1% partial response. 29.4% were off-therapy and 70.6% were receiving anti-leukaemic treatment: induction chemotherapy (25.3%), hypomethylating (19.3%), clinical trial (17.0%), consolidation chemotherapy (14.8%), venetoclax (3.4%), FLT3 inhibitors (3.4%) and/or maintenance (1.1%). Overall, 3.7% were newly diagnosed, 77.8% had received one line of treatment, 14.8% two and 3.7% four. 15.4% had prior allogeneic transplantation.

Only 4.0% of patients were asymptomatic, while the main signs and symptoms were fever (77.8%), pneumonia (75.0%), cough (65.3%), dyspnoea (52.0%), diarrhoea (20.4%), nausea/vomiting (12.2%), rhinorrhoea (10.2%) and headache (7.4%). Analytical parameters were: neutrophils 3112 cells/μL (1900–7300), lymphocytes 1090 cells/μL (1000–3000), interleukin 6 118 pg/mL (0–100), ferritin 4505 ng/mL (15–150) and D-dimer 2823 ng/mL (20–500), with liver enzymes altered in 23.9% of cases. 84.2% received specific treatment for coronavirus infection: chloroquine or hydroxychloroquine (82.2%), lopinavir/ritonavir (54.0%), corticosteroids (39.6%), azithromycin (33.0%), tocilizumab (15.8%), plasma convalescent (3.0%), clinical trial medication (3.0%), remdesivir (2.0%) and/or anakinra (1.0%).

The course was mild in 14.7%, moderate in 32.0% and severe in 53.3%. Mean time to negativisation was 20.5 days, duration of symptoms 17.6 days and hospital stay 11.1 days. In 48.1% of cases treatment for AML was maintained, in 26.6% delayed and in 25.3% modified due to coronavirus disease. 47.5% died, establishing an association between mortality and age over 60 years (58.3% vs 36.4%, p=0.043), ≥2 lines of treatment (72.7% vs 44.3%, p=0.020), active disease (62.5% vs 29.4%, p=0.002) and pneumonia (61.2% vs 22.7%, p=0.002). Overall, 47.5% overcame the infection, and in 5.0% SARS-CoV-2 genetic material was still detected at the time of analysis. A non-significant lower mortality rate was observed among: previous transplantation (45.7% vs 64.3%, p=0.19), neutrophil >1900 cells/μL (41.1% vs 60.0%, p=0.09), lymphocyte >1000 cells/μL (42.9% vs 63.6%, p=0.09) and hydroxychloroquine or chloroquine plus azithromycin (35.3% vs 60.0%, p=0.10).

Conclusion and relevance SARS-CoV-2 infection produced high mortality among AML patients. Mortality was correlated with age, active disease and pneumonia.

References and/or acknowledgements Acknowledgements: Pethema Foundation

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.